<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00486486</url>
  </required_header>
  <id_info>
    <org_study_id>A3241</org_study_id>
    <nct_id>NCT00486486</nct_id>
  </id_info>
  <brief_title>24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination</brief_title>
  <acronym>BTFC</acronym>
  <official_title>A 3-month, 4-centre, Crossover, Double-masked Study Investigating the 24-hour Intraocular Pressure Control With the Bimatoprost/Timolol Fixed Combination Dosed Morning, or Evening in Subjects With Exfoliative Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this crossover, randomized, placebo controlled, double-masked study is to
      compare the short-term (12 weeks) mean 24-hour IOP control and safety of the new fixed
      combination (bimatoprost/timolol, BTFC) given PM with placebo once in the morning, versus
      BTFC given AM with placebo once in the evening versus bimatoprost given in the evening in
      patients with exfoliative glaucoma (XFG).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY STUDY OBJECTIVES

        -  To show that the mean 24-hour IOP control obtained with BTFC (morning or evening) is
           statistically better to that with bimatoprost monotherapy given once on the evening.

        -  To demonstrate that the fixed combination will provide a significantly better IOP
           control in the morning when dosed in the evening.

        -  To test whether the mean 24-hour IOP control obtained with BTFC given once in the
           evening may be statistically better to that with BTFC given once in the morning.

        -  To show whether there will be less 24-hour fluctuation of IOP with the evening dosing of
           BTFC.

      STUDY POPULATION

      Consecutive newly-diagnosed, or suitably washed-out patients with exfoliative glaucoma (XFG)
      who exhibit a mean untreated IOP greater than 25 mm Hg at baseline (10:00).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean 24-hour IOP</measure>
    <time_frame>3 months of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects with medications</measure>
    <time_frame>3 months of therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Bimatoprost/Timolol AM therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimatoprost/Timolol PM therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: bimatoprost/timolol fixed combination AM</intervention_name>
    <description>3-month chronic dosing in the morning</description>
    <arm_group_label>Bimatoprost/Timolol AM therapy</arm_group_label>
    <arm_group_label>Bimatoprost/Timolol PM therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bimatoprost/timolol fixed combination dosed PM</intervention_name>
    <description>Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months</description>
    <arm_group_label>Bimatoprost/Timolol AM therapy</arm_group_label>
    <arm_group_label>Bimatoprost/Timolol PM therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is suffering from XFG (if the patient has bilateral XFG, both eyes will be
             treated, but the worse eye will be selected for the statistical analysis)

          -  Patient is older than 39 years and younger than 85 years

          -  Patient is able and willing to participate in the study for the whole duration of the
             follow up. Will sign the consent form.

          -  At screening the untreated IOP at 10:00 (± 1 hr) is greater than 25 mm Hg and lower
             than 40 mm Hg

          -  After bimatoprost run-in therapy the treated IOP at 10:00 (± 1 hr) is greater than 19
             mm Hg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>39 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anastasios Konstas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of the Glaucoma Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glaucoma Unit, 1st University Department of Ophthalmology</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 36</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma Unit, 1st University Dept of Ophthalmology</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2007</study_first_submitted>
  <study_first_submitted_qc>June 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2007</study_first_posted>
  <last_update_submitted>May 9, 2014</last_update_submitted>
  <last_update_submitted_qc>May 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>AGP Konstas</investigator_full_name>
    <investigator_title>Professor in Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>24-hour IOP control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

